Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 9;12(11):e0187661.
doi: 10.1371/journal.pone.0187661. eCollection 2017.

Durability of immunity by hepatitis B vaccine in Japanese health care workers depends on primary response titers and durations

Nori Yoshioka  1   2 , Matsuo Deguchi  1   2 , Hideharu Hagiya  1 , Masanori Kagita  2 , Hiroko Tsukamoto  2 , Miyuki Takao  2 , Hisao Yoshida  1 , Norihisa Yamamoto  1 , Yukihiro Akeda  1 , Yoshiko Nabetani  1   3 , Ikuhiro Maeda  2 , Yoh Hidaka  2 , Kazunori Tomono  1
Affiliations

Durability of immunity by hepatitis B vaccine in Japanese health care workers depends on primary response titers and durations

Nori Yoshioka et al. PLoS One. .

Abstract

Background: Health care workers (HCWs) are frequently exposed to hepatitis B virus (HBV) infection. The efficacy and safety of immunization with the hepatitis B (HB) vaccine are well recognized, but the durability of immunity and need for booster doses in those with secondary vaccine response failure remains controversial.

Methods: This was a retrospective cohort study performed at Osaka University Hospital, Japan. We examined antibodies against HB surface antigen (anti-HBs) titers annually after immunization for previously non-immunized HCWs. Primary responders were categorized by their sero-positive durations as short responders (those whose anti-HBs titers declined to negative range within 3 years), and long responders (those who retained positive anti-HBs levels for 3 years and more). We re-immunized short responders with either single or 3-dose boosters, the long responders with a single booster when their titers dropped below protective levels, and examined their sero-protection rates over time thereafter.

Results: From 2001 to 2012, data of 264 HCWs with a median age of 25.3 were collected. The rate of anti-HBs positivity after primary vaccination were 93.0% after three doses (n = 229), 54.5% after two doses (n = 11), and 4.2% after a single dose (n = 24). Of 213 primary responders, the anti-HBs levels of 95 participants (44.6%) fell below the protective levels, including 46 short responders and 49 long responders. HCWs with higher initial anti-HBs titers after primary vaccination had significantly longer durations of sero-positivity. For short responders, 3-dose booster vaccination induced a longer duration of anti-HBs positivity compared to a single-dose booster, whereas for long responders, a single-dose booster alone could induce prolonged anti-HBs positivity.

Conclusion: Our preliminary data suggested that it may be useful to differentiate HB vaccine responders based on their primary response durations to maintain protective levels of anti-HBs efficiently. A randomized, prospective, large-scale study is warranted to support our findings.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow of the study.
Individuals who retained positive anti-HBs titers for >3 years were regarded as long responders and those who did not were regarded as short responders.
Fig 2
Fig 2. Doses of primary hepatitis B vaccine and rate of anti-HBs positivity.
Fig 3
Fig 3. Initial anti-HBs titers of primary responders after full series of vaccination and its duration of positivity.
(A) A box indicates a median and interquartile range, and error bars denote the 10th and 90th percentiles. (B) High (> 500 mIU/mL, n = 35), moderate (100–500 mIU/mL, n = 62), and low (< 100 mIU/mL, n = 46) titers. It was a significant trend that individuals with lower titers of initial anti-HBs experienced secondary vaccine response failure earlier.
Fig 4
Fig 4. Booster doses administered to short/long responders and duration of anti-HBs positivity.
See this image and copyright information in PMC

References

    1. Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053–2063. doi: 10.1016/S0140-6736(14)60220-8 - DOI - PubMed
    1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–1555. doi: 10.1016/S0140-6736(15)61412-X - DOI - PubMed
    1. Bond W, Favero M, Petersen N, Gravelle C, Ebert J, Maynard J. Survival of hepatitis B virus after drying and storage for one week. Lancet. 1981;317:550–551. - PubMed
    1. Meireles LC, Marinho RT, Van Damme P. Three decades of hepatitis B control with vaccination. World J Hepatol. 2015;7:2127 doi: 10.4254/wjh.v7.i18.2127 - DOI - PMC - PubMed
    1. Jack A, Hall A, Maine N, Mendy M, Whittle H. What level of hepatitis B antibody is protective? J Infect Dis. 1999;179:489–492. doi: 10.1086/314578 - DOI - PubMed

LinkOut - more resources